cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-2023Research ArticleОБЗОРЫREVIEWSАнтитромбоцитарная терапия при ишемической болезни сердцаAnti-platelet therapy in coronary heart diseaseЕрмаковаО. В.ErmakovaO. V.

мл. н.с. лаборатории оптимизации медикаментозной профилактики в первичном здравоохранении отдела профилактики в первичном звене здравоохранения

КокуринаЕ. В.KokurinaE. V.

вед. н.с.

ekokurina@gnicpm.ruКучеряваяН. Г.KucheryavayaN. G.

ст. н.с.

БочкареваЕ. В.BochkarevaE. V.

руководитель

Государственный научно-исследовательский центр профилактической медицины Росмедтехнологии. МоскваState Research Centre for Preventive Medicine, Federal Agency on High Medical Technologies. Moscow2010200220109197106Copyright © Ермакова О.В., Кокурина Е.В., Кучерявая Н.Г., Бочкарева Е.В., 20102010Ермакова О.В., Кокурина Е.В., Кучерявая Н.Г., Бочкарева Е.В.Ermakova O.V., Kokurina E.V., Kucheryavaya N.G., Bochkareva E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/2023

Применение новой отечественной формы ацетилсалициловой кислоты (АСК) препарата Асколонг может существенно увеличить приверженность пациентов длительной антиагрегантной терапии. Асколонг в дозе 12,5 мг при его трансмукозном поступлении из полости рта в системное кровообращение практически не оказывает отрицательного действия на слизистую оболочку желудочно-кишечного тракта, являющегося основной причиной отказа больных от лечения многими пероральными формами АСК. Асколонг обладает таким же антиагрегантным действием, как и современный кишечнорастворимый препарат АСК ТромбоАСС, содержащий в 8 раз большую, чем асколонг дозу АСК и оказывающий раздражающее действие на слизистую оболочку гастродуоденальной зоны у 40% больных.

A new, produced in Russia, form of acetylsalicylic acid (ASA), Askolong, could substantially improve patients’ compliance to long-term anti-aggregant therapy. Oral Askolong (12,5 mg) is absorbed via oral mucosa and does not cause gastrointestinal adverse effects, which are the main reason for treatment discontinuation in patients prescribed most oral ASA forms. Askolong demonstrates anti-aggregant effects similar to those for intestinally absorbed ASC medication ThromboASS. The latter dose of ASA is eight times higher, and gastrointestinal adverse effects are registered in 40% of the patients.

новые формы ацетилсалициловой кислотыантиагрегантный эффектпобочные явленияАсколонгnew forms of acetylsalicylic acidanti-aggregant effectadverse effectsAskolongReferencesБалуда В. П., Деянов И.И. Значение определения антитромбогенных свойств стенки сосудов в практике тромбозов. Кардиология 1988; 5: 103-5.Балуда В. П., Деянов И.И. Значение определения антитромбогенных свойств стенки сосудов в практике тромбозов. Кардиология 1988; 5: 103-5.Касаткина Л. В., Владимиров С.С. Маркосян Р.А., Матвеева Л.С. Агрегационная способность тромбоцитов у больных ИБС, обусловленной коронарным атеросклерозом. Кардиология 1987; 7: 49-53.Касаткина Л. В., Владимиров С.С. Маркосян Р.А., Матвеева Л.С. Агрегационная способность тромбоцитов у больных ИБС, обусловленной коронарным атеросклерозом. Кардиология 1987; 7: 49-53.Кокурина Е.В., Метелица В.И., Суслина З.А. и др. Перспективы развития новых лекарственных форм аспирина. Асколонг -пленочная форма для буквального применения. Тезисы докладов V Российского Национального Конгресса "Человек и лекарство". Москва 1998; 494.Кокурина Е.В., Метелица В.И., Суслина З.А. и др. Перспективы развития новых лекарственных форм аспирина. Асколонг -пленочная форма для буквального применения. Тезисы докладов V Российского Национального Конгресса "Человек и лекарство". Москва 1998; 494.Малая Л.Т., Ефимов В.В., Ладный А.И. Роль простациклин-тромбоксановой системы в патогенезе атеросклероза. В сб. докл. ГУ Всесоюзн съезда кардиологов. Москва 1986; 14-5.Малая Л.Т., Ефимов В.В., Ладный А.И. Роль простациклин-тромбоксановой системы в патогенезе атеросклероза. В сб. докл. ГУ Всесоюзн съезда кардиологов. Москва 1986; 14-5.Ферстрате М., Фермилен Ж. Тромбозы (пер. с англ. Кабаевой Е.В. под редакцией Бокарева И.Н.). Москва "Медицина" 1986; 333 с.Ферстрате М., Фермилен Ж. Тромбозы (пер. с англ. Кабаевой Е.В. под редакцией Бокарева И.Н.). Москва "Медицина" 1986; 333 с.Хатиашвили Н.С. Эриашвили В.М. Методы индивидуализации и оптимизации применения лекарств на основе изучения их фармакокинетики. Москва 1982; 113-4.Хатиашвили Н.С. Эриашвили В.М. Методы индивидуализации и оптимизации применения лекарств на основе изучения их фармакокинетики. Москва 1982; 113-4.Чазов Е.И., Смирнов В.Н. Стенка сосудов в атеро-и тром-богенезе. Москва 1983.Чазов Е.И., Смирнов В.Н. Стенка сосудов в атеро-и тром-богенезе. Москва 1983.Чирятьев Е.А., Левкин А.Н., Мухачев А. И., Бырышевский А.Ш. О регуляции агрегатного состояния крови на уровне самосборки фибрина. Актуальные проблемы гемостаза в клинической практике: Тезисы докл симп. Москва 1987; 131.Чирятьев Е.А., Левкин А.Н., Мухачев А. И., Бырышевский А.Ш. О регуляции агрегатного состояния крови на уровне самосборки фибрина. Актуальные проблемы гемостаза в клинической практике: Тезисы докл симп. Москва 1987; 131.Шабалов Н.П., Болотина Е.Д. Ацетилсалициловая кислота и функции тромбоцитов. Педиатрия 1984; 9: 29-30.Шабалов Н.П., Болотина Е.Д. Ацетилсалициловая кислота и функции тромбоцитов. Педиатрия 1984; 9: 29-30.Abajo F.J., Rodriguez L.A. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulation. BMC Clin Pharmac 2001; 1: 1-9.Abajo F.J., Rodriguez L.A. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulation. BMC Clin Pharmac 2001; 1: 1-9.Anderson G.H., Heliums J.D., Moake J. Platelet response to shear stress: changes in serotonin uptake, serotonin release and ADP -induced aggregation. Thromb Res 1978; 13: 1039-47.Anderson G.H., Heliums J.D., Moake J. Platelet response to shear stress: changes in serotonin uptake, serotonin release and ADP -induced aggregation. Thromb Res 1978; 13: 1039-47.Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy -III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Br Med J 1994; 308: 235-46.Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy -III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Br Med J 1994; 308: 235-46.Antithrombotic Trialists' Collaboration Group. Collaborative metaanalysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.Antithrombotic Trialists' Collaboration Group. Collaborative metaanalysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.Bushfield D., Tomich E.G. Reduction of platelet adhesiveness by adenjsine diphosphate and triphosphate. Nature 1967; 214: 1360-1.Bushfield D., Tomich E.G. Reduction of platelet adhesiveness by adenjsine diphosphate and triphosphate. Nature 1967; 214: 1360-1.Cerletti C. Biochemical Selectivity of Oral Versus Intravenous Aspirin in Rats. Clinic Invest 1986; 78: 323-6.Cerletti C. Biochemical Selectivity of Oral Versus Intravenous Aspirin in Rats. Clinic Invest 1986; 78: 323-6.Clopidogrel in Unstable Angina to Prevrnt Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.Clopidogrel in Unstable Angina to Prevrnt Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.Dalai I., Penny W., Sheridan D. Platelet aggregation during myocardial ischemia. In proc. IX World Congr Cardiol 1982; 1: Abstr. N. 506.Dalai I., Penny W., Sheridan D. Platelet aggregation during myocardial ischemia. In proc. IX World Congr Cardiol 1982; 1: Abstr. N. 506.Fox K.A. Thrombosis in myocardial infarction. Trombosis Research 1992; 65(Suppl. 1): Abst. S-46.Fox K.A. Thrombosis in myocardial infarction. Trombosis Research 1992; 65(Suppl. 1): Abst. S-46.Gallino A., Haeberli A., Baur H. Fibrin formation and platelet aggregation in patients with severe coronary artery disease. Thromb Haemost 1985; 54(1): 155.Gallino A., Haeberli A., Baur H. Fibrin formation and platelet aggregation in patients with severe coronary artery disease. Thromb Haemost 1985; 54(1): 155.Gertz S.D., Uretsky G., Wajnberg R.S., et al. Endothelial cell damage and thrombus formatijn after partial arterial constriction: relevance to the role of coronary artery spasm in the pathogntsis of miocardial infarction. Circulation 1981; 63: 476-86.Gertz S.D., Uretsky G., Wajnberg R.S., et al. Endothelial cell damage and thrombus formatijn after partial arterial constriction: relevance to the role of coronary artery spasm in the pathogntsis of miocardial infarction. Circulation 1981; 63: 476-86.Hansson L., Zanchetti F., Carruthers, et al. Effects of intensive bloodpressure lowering and low-dose aspirin in patients with hypertension: principle results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62.Hansson L., Zanchetti F., Carruthers, et al. Effects of intensive bloodpressure lowering and low-dose aspirin in patients with hypertension: principle results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62.Hantagan R.R. A stady of the mechanism of platelet aggregation: fibrin and fibrinolen as cofactors. Trombos Haemostas 1985; 54 (I): 236.Hantagan R.R. A stady of the mechanism of platelet aggregation: fibrin and fibrinolen as cofactors. Trombos Haemostas 1985; 54 (I): 236.Jefferson B.K., Foster Jh., McCarthy J.J., et al. Aspirin resistance and a singl gene. AM J Cardiol 2005; 95: 805-8.Jefferson B.K., Foster Jh., McCarthy J.J., et al. Aspirin resistance and a singl gene. AM J Cardiol 2005; 95: 805-8.Jha S. Effect of variable doses of aspirin on platelet function. J Assoc Physicians India 1989; 37: 4: 269-70.Jha S. Effect of variable doses of aspirin on platelet function. J Assoc Physicians India 1989; 37: 4: 269-70.Juul-Moller S., Edvardsson N., Jahanatz B., et al. Doudle-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable angina pectoris. Lancet 1992; 340: 1421-5.Juul-Moller S., Edvardsson N., Jahanatz B., et al. Doudle-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable angina pectoris. Lancet 1992; 340: 1421-5.Kelton J., Carter C., Buchanan M.R., Hirsh J. Trombogenic effect of high dose aspirin in injury induced experimental venous trombosis. Clin Res 1978; 26(3): 350 A.Kelton J., Carter C., Buchanan M.R., Hirsh J. Trombogenic effect of high dose aspirin in injury induced experimental venous trombosis. Clin Res 1978; 26(3): 350 A.Lanza F.L., Royer G.L., Nelson R.S. Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric coated aspirin on gastric ahd duodenal mucosa. N Engl J Med 1980; 303, 136.Lanza F.L., Royer G.L., Nelson R.S. Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric coated aspirin on gastric ahd duodenal mucosa. N Engl J Med 1980; 303, 136.Lotti T., Campanile G., Ghersetich I. Endotelium-blood cell interactions in thrombosis. Trombosis Research 1992; 65(Suppl.): Abst. S 56.Lotti T., Campanile G., Ghersetich I. Endotelium-blood cell interactions in thrombosis. Trombosis Research 1992; 65(Suppl.): Abst. S 56.Mustard I., Kinglough-Rathbone R, Packham M. Mechanism in trombosis. Agents and actions 1984; 15: 9-23.Mustard I., Kinglough-Rathbone R, Packham M. Mechanism in trombosis. Agents and actions 1984; 15: 9-23.Clagett P.G., Russo M., Hufnagel H. Aspirine dosage and antithrombotic effect. Thrombos Haemostas 1979; 1(42): 60.Clagett P.G., Russo M., Hufnagel H. Aspirine dosage and antithrombotic effect. Thrombos Haemostas 1979; 1(42): 60.Peto R., Gray R., Collins R., et al. Randomized trial of prophylactic daily aspirin on British male doctors. BMJ 1988; 296: 313-6.Peto R., Gray R., Collins R., et al. Randomized trial of prophylactic daily aspirin on British male doctors. BMJ 1988; 296: 313-6.Poungvarin N. Low dose aspirin and its antithrombotic effect in ischaemic stroke patient. J Med Assoc Thai 1989; 72(8): 421-6.Poungvarin N. Low dose aspirin and its antithrombotic effect in ischaemic stroke patient. J Med Assoc Thai 1989; 72(8): 421-6.Preston F.E. Low -dose aspirin inhibits platelet and venous cyclooxygenase in men. Thromb Res 1982; 27: 477-84.Preston F.E. Low -dose aspirin inhibits platelet and venous cyclooxygenase in men. Thromb Res 1982; 27: 477-84.Ridker P., Cook N., Min Lee I., et al. A randomized trial of low-dose aspirin in primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352.Ridker P., Cook N., Min Lee I., et al. A randomized trial of low-dose aspirin in primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352.Roberts M.S., McLeod L.J. Inhibition of Platelet Function by a Controlled Release Acetylsalicylic Acid Formulation -Sihgl and Chronic dosihg Studies. Eur J Clin Pharmacol 1984; 27: 67-74.Roberts M.S., McLeod L.J. Inhibition of Platelet Function by a Controlled Release Acetylsalicylic Acid Formulation -Sihgl and Chronic dosihg Studies. Eur J Clin Pharmacol 1984; 27: 67-74.Salvati P., Dho, Ukmar G. Additive antithrombotic effect of a thromboxane -synthase inhibitor associated to a fully effective dose of a Tx A2 -receptor antagonist; comparison with aspirin. Thromb Haemostas 1992; 65(Suppl.l): Abst С 80.Salvati P., Dho, Ukmar G. Additive antithrombotic effect of a thromboxane -synthase inhibitor associated to a fully effective dose of a Tx A2 -receptor antagonist; comparison with aspirin. Thromb Haemostas 1992; 65(Suppl.l): Abst С 80.Samama C.M., Bonnin P. Bonneau M. Comparative arterial antithrombotic activity of clopidogrel and acetylsalicylic acid in the pig. Trombosis Research 1992; 65(Suppl. 1): Abst С 82.Samama C.M., Bonnin P. Bonneau M. Comparative arterial antithrombotic activity of clopidogrel and acetylsalicylic acid in the pig. Trombosis Research 1992; 65(Suppl. 1): Abst С 82.Santos M.T., Valles I., Aznar I. Rolle of red blood cells in the early stages of platelet activation by collagen. Trombos Haemostas 1986; 54 (III): 376-81.Santos M.T., Valles I., Aznar I. Rolle of red blood cells in the early stages of platelet activation by collagen. Trombos Haemostas 1986; 54 (III): 376-81.Schr r K. Aspirin. Thieme Stuttgart-New York 1992.Schr r K. Aspirin. Thieme Stuttgart-New York 1992.Sreering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. New Engl J Med 1989; 321: 129-35.Sreering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. New Engl J Med 1989; 321: 129-35.The SALT Collaborative Group. Swedish aspirin low-dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischeaemic events. Lancet 1991; 338: 1345-9.The SALT Collaborative Group. Swedish aspirin low-dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischeaemic events. Lancet 1991; 338: 1345-9.Valles J., Santos M.T., Aznar J. Effect of aspirin on platelet -erythrocyte interactions induced by collagen. Trombosis Research 1992; 65(Suppl. 1): Abst С 169.Valles J., Santos M.T., Aznar J. Effect of aspirin on platelet -erythrocyte interactions induced by collagen. Trombosis Research 1992; 65(Suppl. 1): Abst С 169.Vandeplassche G., Hermans C., Van Gael L. Combined Tx A2 synthase/Pg H2 endoperoxide receptor antagonism limits myocardial infarct size at doses enhancing coronary thrombolysis by streptokinase. Thromb Res 1992; 65(Suppl.l): Abst С 142.Vandeplassche G., Hermans C., Van Gael L. Combined Tx A2 synthase/Pg H2 endoperoxide receptor antagonism limits myocardial infarct size at doses enhancing coronary thrombolysis by streptokinase. Thromb Res 1992; 65(Suppl.l): Abst С 142.Vane J.R. Inhibition of prostaglandinsysntheesis as a mechanism of action of aspirin -like drugs. Nature New Biol 1971; 231: 232-5.Vane J.R. Inhibition of prostaglandinsysntheesis as a mechanism of action of aspirin -like drugs. Nature New Biol 1971; 231: 232-5.Vane J.R., Botting R.M. (Hrsg). Aspirin and other salicylates. Chapman & Hall Medical: London 1992.Vane J.R., Botting R.M. (Hrsg). Aspirin and other salicylates. Chapman & Hall Medical: London 1992.Vargaftig B.B., Chighard M., Benveniste I. Present concept -the mechanism of platelet aggregation. Biochem Pharmac 1981; 30: 263-71.Vargaftig B.B., Chighard M., Benveniste I. Present concept -the mechanism of platelet aggregation. Biochem Pharmac 1981; 30: 263-71.Wegmuller E. Nicht -steroidale Antipheumatika und Nephrotoxizitat. Dtsch med Wschr 1985; 110: 469-72.Wegmuller E. Nicht -steroidale Antipheumatika und Nephrotoxizitat. Dtsch med Wschr 1985; 110: 469-72.World Health Organisation -International Society of Hypertension. Guidelines for the management of Hypertension. Hypertension 1999; 17: 151-83.World Health Organisation -International Society of Hypertension. Guidelines for the management of Hypertension. Hypertension 1999; 17: 151-83.Yang Z. Platelet -vessel wall interaction in health and disease. Role of tromboxane A2 and serotonin. Thrombosis Research 1992; 65(Suppl.l): Abst.S -33.Yang Z. Platelet -vessel wall interaction in health and disease. Role of tromboxane A2 and serotonin. Thrombosis Research 1992; 65(Suppl.l): Abst.S -33.Zucker M.B., Peterson J. Effect of acetylsalicylic acid, other nonsteroidal anti-inflammatory agents and dipyridamole on human blood platelets. J Lab Clin Med 1970; 76: 66-75.Zucker M.B., Peterson J. Effect of acetylsalicylic acid, other nonsteroidal anti-inflammatory agents and dipyridamole on human blood platelets. J Lab Clin Med 1970; 76: 66-75.

The authors declare that there are no conflicts of interest present.